Farampator

Farampator

Systematic (IUPAC) name
2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone
Clinical data
Legal status	Investigational New Medicine
Identifiers
CAS Registry Number	211735-76-1 Y
ATC code	None
PubChem	CID 4118151
ChemSpider	3331565 N
UNII	7X6P5N8K2L N
KEGG	D04131 Y
Synonyms	Farampator, CX-691
Chemical data
Formula	C12H13N3O2
Molecular mass	231.25052 g/mol
SMILES C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2
InChI InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2  N Key:XFVRBYKKGGDPAJ-UHFFFAOYSA-N  N
N (what is this?)  (verify)

Farampator (CX-691, Org 24448) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator has been transferred, and development is continuing.

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's Disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects (SEs) such as headache, somnolence and nausea. Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs. Additional analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs. ^[1]

References